Global Facilities Engineering & Projects Leader

At Illumina, groundbreaking technology is revolutionizing the understanding of genetic variation and biological function. Since its inception in 1998, Illumina has been at the forefront of developing, manufacturing, and marketing integrated systems for the analysis of genetic material. The company's relentless focus on innovation has established it as a global leader in DNA sequencing and array-based technologies, serving a diverse range of customers in research, clinical, and applied markets. Illumina's technologies are pivotal in driving advancements in life science research, translational and consumer genomics, and molecular diagnostics. The company's mission is to improve human health by unlocking the power of the genome, a commitment that fuels its continuous push to expand the boundaries of genomic possibility. This dedication enables researchers and clinicians worldwide to accelerate their discoveries and develop applications that heal people and the planet.

Illumina's innovative spirit is evident in its extensive portfolio of products and services, which includes sequencing instruments, consumables, and services that account for the majority of its revenue. These cutting-edge tools, such as the NovaSeq and MiSeq series, facilitate high-throughput whole-genome sequencing in humans and other large organisms, as well as targeted applications like viral and cancer tumor screening. The company also provides microarray-based products for SNP genotyping, gene expression, and protein analysis. With over 9,000 patents, Illumina has become a catalyst for its customers and partners, contributing to hundreds of thousands of studies featured in peer-reviewed scientific publications. Illumina's impact extends across various fields, including oncology, reproductive health, genetic and infectious diseases, agriculture, and forensic science, empowering global innovation and revolutionizing health on a massive scale. The company actively collaborates with academic institutions, pharmaceutical companies, clinical research organizations, and biotechnology companies to further the reach and impact of genomic science.